FDA’s Biosimilars Action Plan
In July 2018, FDA released the Biosimilars Action Plan (BAP), which outlined FDA’s approach for ...
Thursday, November 21, 2024
Tag: biosimilars
Are providers ready for biosimilars?
Perhaps more education is needed. That is the conclusion from a paper by Giovatto et ...
FDA Approves Sandoz Biosimilars for Two Blockbuster Amgen Bone Drugs
A blockbuster Amgen antibody that treats bone conditions is set to face its first biosimilar competition. The FDA on Tuesday ...
Utilization management for biosimilars
When we think of utilization management (e.g., prior authorizations, step edits), we often think payers only use these for higher ...